Joey Perrone
About Joey Perrone
Joey Perrone serves as the Senior Vice President of Finance and Investor Relations at Day One Biopharmaceuticals, a position he has held since 2022. With a background in finance spanning over a decade, he has previously worked at various companies including Aeglea BioTherapeutics and Astrotech Corporation.
Work at Day One Biopharmaceuticals
Joey Perrone serves as the Senior Vice President of Finance and Investor Relations at Day One Biopharmaceuticals. He has held this position since 2022, contributing to the company's financial strategy and investor communications. His role involves overseeing financial planning, reporting, and managing relationships with investors, ensuring transparency and effective communication regarding the company's financial performance.
Education and Expertise
Joey Perrone holds an MBA in Business Administration from The University of Texas at Austin, where he studied from 2009 to 2012. He also completed his undergraduate studies at Trinity University from 2001 to 2005. His educational background provides a strong foundation in finance and business management, which he applies in his professional roles.
Background in Finance
Joey Perrone has extensive experience in finance and investor relations, having worked in various capacities across multiple organizations. His career includes roles such as Sr. Director of Finance and Investor Relations at Aeglea BioTherapeutics from 2015 to 2021 and Assistant Controller at Astrotech Corporation for five months in 2012. He has also held positions as an Accountant at Temple Inland Inc. and a Financial Analyst at ArthroCare Corporation.
Career Progression
Joey Perrone's career in finance has seen him progress through various roles with increasing responsibilities. He started as an Accountant at Temple Inland Inc. and moved on to become a Financial Analyst at ArthroCare Corporation. He later took on roles at Astrotech Corporation, including Director of FP&A and Senior Analyst, before advancing to senior leadership positions at Aeglea BioTherapeutics and Day One Biopharmaceuticals.